Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial to investigate JHL1922 in cystic fibrosis patients.

Trial Profile

A phase 3 trial to investigate JHL1922 in cystic fibrosis patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2018 According to a JHL Biotech media release, this trial is expected to begin in 2019.
    • 05 Feb 2018 New trial record
    • 01 Feb 2018 According to a JHL Biotech media release, company plans to initiate this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top